The role of clinical pharmacology in the development and assessment of drugs for cerebrovascular disease and stroke.
作者： JL Reid
DOI: 10.1111/J.1365-2125.1993.TB04148.X
关键词: Clinical trial 、 Investigation methods 、 Stroke 、 Fibrinolytic agent 、 Intensive care medicine 、 Medicine 、 Surgery 、 Clinical pharmacology
摘要:
sci-hub.se 参考文章(6)
DG Grosset, Clinical, radiological, and functional evaluation following acute stroke. British Journal of Clinical Pharmacology. ,vol. 34, pp. 477- 485 ,(1992) , 10.1111/J.1365-2125.1992.TB05654.X
R. Bullock, Introducing NMDA antagonists into clinical practice: why head injury trials? British Journal of Clinical Pharmacology. ,vol. 34, pp. 396- 401 ,(1992) , 10.1111/J.1365-2125.1992.TB05648.X
J McCulloch, Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. British Journal of Clinical Pharmacology. ,vol. 34, pp. 106- 114 ,(1992) , 10.1111/J.1365-2125.1992.TB04118.X
Macrae I Mhairi, New models of focal cerebral ischaemia. British Journal of Clinical Pharmacology. ,vol. 34, pp. 302- 308 ,(1992) , 10.1111/J.1365-2125.1992.TB05634.X
KR Lees, Therapeutic interventions in acute stroke. British Journal of Clinical Pharmacology. ,vol. 34, pp. 486- 493 ,(1992) , 10.1111/J.1365-2125.1992.TB05655.X
BJ Alps, Drugs acting on calcium channels: potential treatment for ischaemic stroke. British Journal of Clinical Pharmacology. ,vol. 34, pp. 199- 206 ,(1992) , 10.1111/J.1365-2125.1992.TB04125.X